These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 38190498

  • 1. Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort.
    Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Ben-Tov A, Loewenberg Weisband Y, Matz E, Gorelik Y, Chowers Y, Dotan I, Turner D.
    Inflamm Bowel Dis; 2024 Nov 04; 30(11):2097-2104. PubMed ID: 38190498
    [Abstract] [Full Text] [Related]

  • 2. Durability of the First Biologic in Patients with Crohn's Disease: A Nationwide Study from the epi-IIRN.
    Atia O, Friss C, Focht G, Magen Rimon R, Ledderman N, Greenfeld S, Ben-Tov A, Loewenberg Weisband Y, Matz E, Gorelik Y, Chowers Y, Dotan I, Turner D.
    J Crohns Colitis; 2024 Jan 27; 18(1):38-46. PubMed ID: 37465992
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P.
    Aliment Pharmacol Ther; 2016 Nov 27; 44(10):1102-1113. PubMed ID: 27666569
    [Abstract] [Full Text] [Related]

  • 7. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    Inflamm Bowel Dis; 2024 Oct 03; 30(10):1776-1787. PubMed ID: 37921344
    [Abstract] [Full Text] [Related]

  • 8. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S, Andersen NN, Andersson M, Loftus EV, Jess T.
    Aliment Pharmacol Ther; 2018 Mar 03; 47(5):596-604. PubMed ID: 29239001
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C.
    Lancet Gastroenterol Hepatol; 2021 Dec 03; 6(12):1002-1014. PubMed ID: 34688373
    [Abstract] [Full Text] [Related]

  • 10. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS, PRO-KIIDS Research Group.
    Gastroenterology; 2014 Feb 03; 146(2):383-91. PubMed ID: 24162032
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M, Nice R, Lees CW, Sebastian S, Irving PM, Russell RK, McDonald TJ, Goodhand JR, Ahmad T, Kennedy NA, PANTS Consortium.
    Lancet Gastroenterol Hepatol; 2024 Jun 03; 9(6):521-538. PubMed ID: 38640937
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.
    Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT.
    BMC Gastroenterol; 2024 Sep 17; 24(1):314. PubMed ID: 39289603
    [Abstract] [Full Text] [Related]

  • 16. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, UK Inflammatory Bowel Disease Pharmacogenetics Study Group.
    Lancet Gastroenterol Hepatol; 2019 May 17; 4(5):341-353. PubMed ID: 30824404
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.
    J Crohns Colitis; 2016 May 17; 10(5):516-24. PubMed ID: 26802084
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.